Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G. Schwartz(Denver VA Medical Center), Andreas M. Zeiher(Goethe University Frankfurt), Deepak L. Bhatt(Brigham and Women's Hospital), Rafael Díaz(Estudios Clínicos Latinoamérica), Pierluigi Tricoci(Inserm), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Robert Pordy(Inserm), Shaun G. Goodman(St. Michael's Hospital), Vera Bittner, Robert A. Harrington(Clinical Research Institute), Harvey D. White(University of Auckland), Michael Szarek(State University of New York), Jay M. Edelberg(Inserm), Angèle Moryusef(Inserm), William J. Sasiela(Inserm), Corinne Hanotin, Kirby Quintero(Inserm), Matthew T. Roe(Inserm), Jean‐François Tamby(Inserm), Philippe Gabríel Steg(Sorbonne Paris Cité), Guillaume Lecorps(Inserm), J. Wouter Jukema(Inserm)
Cited by 3,505
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k